Epigenetic Biomarkers In Neurodegenerative Diseases is an important topic in neurodegenerative disease research. This page provides comprehensive information about its relevance, mechanisms, and implications for the field.
Epigenetic biomarkers measure modifications to DNA and histone proteins that regulate gene expression without changing the underlying DNA sequence. These biomarkers are increasingly important for understanding neurodegenerative disease mechanisms and may serve as diagnostic or progression markers.[1]
| Gene | Change | Direction | Clinical Relevance |
|---|---|---|---|
| APP | Hypomethylation | Decreased | Early detection |
| MAPT | Hypermethylation | Increased | Tau pathology |
| BDNF | Hypomethylation | Decreased | Synaptic dysfunction |
| RELN | Hypomethylation | Decreased | Tau pathology |
| S100A2 | Hyper | Increased | Diagnostic marker |
| Gene | Change | Pathway |
|---|---|---|
| SNCA | Hypomethylation | α-syn expression |
| PARK16 | Hypermethylation | Risk locus |
| LRRK2 | Variable | kinase regulation |
| GCH1 | Hypomethylation | DOPA synthesis |
| MAOB | Hypermethylation | Dopamine metabolism |
| Gene | Change | Notes |
|---|---|---|
| C9orf72 | Expansion + methylation | Toxicity |
| SOD1 | Variable | Mutation-specific |
| ATXN2 | Hypermethylation | Risk factor |
| OPTN | Hypomethylation | Autophagy |
| Disease | Epigenetic Marker | Sample | Sensitivity | Specificity |
|---|---|---|---|---|
| AD | Multi-gene panel | Blood | ~85% | ~80% |
| PD | SNCA methylation | Blood | ~75% | ~70% |
| ALS | C9orf72 methylation | Blood | ~95% | ~90% |
| HD | HTT methylation | Blood | ~98% | ~95% |
| Method | Coverage | Advantages |
|---|---|---|
| Bisulfite-seq | Genome-wide | High resolution |
| 450K/850K Arrays | CpG sites | Cost-effective |
| Reduced Representation | Targeted | Deep coverage |
| Oxford Nanopore | Direct | Long reads |
| single-cell | Cell-type | Resolution |
The study of Epigenetic Biomarkers In Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Iwata A, et al. "Epigenetic biomarkers for neurodegenerative diseases." Nat Rev Neurol. 2023. ↩︎
Peschel N, et al. "DNA methylation in neurodegeneration." Nat Rev Neurosci. 2022. ↩︎
De Jager PL, et al. "Alzheimer's disease epigenetics." Mol Brain. 2022. ↩︎
Chuang YH, et al. "Parkinson's disease DNA methylation." Neurology. 2022. ↩︎
Zhang M, et al. "ALS epigenetics." Brain. 2021. ↩︎
std
HDAC inhibitors for Huntington's disease: clinical potential. Cell. 2020. ↩︎
Qureshi IA, Mehler MF. "Epigenetics of neurodegeneration." Nat Rev Neurol. 2018. ↩︎
Lockhart PJ, et al. "Epigenetic biomarker development." Genome Med. 2023. ↩︎